Evenity (romosozumab) is given as two subcutaneous injections once a month, each containing 105 mg of the drug for a combined monthly dose of 210 mg. The injections are administered consecutively during a single clinic visit, typically by a healthcare professional, and the full course of treatment lasts 12 months. That straightforward dosing schedule, though, comes with a set of safety considerations that anyone starting the drug should understand thoroughly.
What the Injections Look Like in Practice
Each monthly appointment involves two separate shots delivered just under the skin. The injection sites are usually the abdomen, thigh, or upper arm, and the two shots should be given in different locations rather than side by side in the same spot.1Doctor Medica. How Is Evenity Administered: Shots, Schedule & Safety The medication comes in prefilled syringes, and each one delivers 105 mg. Because you need two syringes to reach the 210 mg dose, both are given back to back during the same office visit. Unlike some osteoporosis treatments that require infusion centers or self-injection at home, Evenity is designed to be administered by a nurse or other qualified provider, though self-injection is possible once you have been trained.
The injections themselves are subcutaneous, meaning the needle goes into the fatty tissue beneath the skin rather than into a muscle or vein. This generally makes them less painful than intramuscular shots, though some people do experience soreness, redness, or swelling at the injection site. In one study that tracked injection-site reactions, about a quarter of patients experienced them within the first six months of treatment.2PubMed Central. Is Early Injection-Site Reaction Associated With the Efficacy of Romosozumab? These reactions are typically mild and resolve on their own.
The 12-Month Treatment Window
Evenity is not an indefinite medication. The course of treatment is 12 monthly doses, and then it stops. This time limit exists because the drug’s bone-building effect diminishes over the course of the year. Romosozumab works by blocking a protein called sclerostin, which normally acts as a brake on bone formation. When you remove that brake, bone-building cells ramp up activity dramatically. But the body gradually adapts, and the surge in new bone formation peaks in the first few months before tapering off.
Research on bone turnover markers illustrates this pattern clearly. One study found that a marker of bone formation called P1NP surged early in treatment, with the value at month three being the strongest predictor of how much bone density patients ultimately gained by the end of the year.3Oxford Academic / Modern Rheumatology. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab That same study reported average bone density gains of about 17.5% at the lumbar spine and 8.1% at the total hip over 12 months, which are substantial increases by osteoporosis treatment standards.
The finite treatment window also means that what comes after Evenity matters just as much as the treatment itself. Bone density gains can reverse if you simply stop without transitioning to another medication. The standard approach is to follow the 12-month course with an antiresorptive drug, most commonly denosumab or a bisphosphonate, to preserve the newly built bone.
How Well It Works Across Different Ages
A reasonable concern for anyone considering Evenity is whether it works as well in older patients as in younger ones. A prospective study of 221 treatment-naïve Japanese women ranging from age 55 to 100 examined this directly, tracking bone density changes and bone turnover markers at 6 and 12 months of romosozumab therapy.4PubMed. Age-related response to 12-month romosozumab in treatment-naïve Japanese women aged 55-100 years with primary osteoporosis The study measured changes at the lumbar spine, total hip, and femoral neck, which are the three sites where fractures cause the most disability. The inclusion of centenarians in the study population speaks to the drug’s use in genuinely elderly patients, a group often excluded from clinical trials.
Data from the FRAME trial’s Japanese subgroup showed that romosozumab followed by denosumab reduced the incidence of new vertebral fractures compared to placebo followed by denosumab, with a relative risk reduction of 84% at all measured timepoints through 36 months.5PubMed. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial The p-value for that result was 0.056, sitting right at the edge of conventional statistical significance, which partly reflects the smaller sample size of a regional subgroup rather than a lack of real effect. The broader FRAME trial, which enrolled thousands of postmenopausal women globally, showed clear fracture reduction.
Patients Switching from Other Osteoporosis Drugs
Many people prescribed Evenity have already tried other osteoporosis medications, and the drug’s effectiveness can vary depending on what you were taking before. The STRUCTURE trial compared romosozumab to teriparatide in postmenopausal women who had previously been on bisphosphonates. At 12 months, only 3% of romosozumab-treated patients showed no gain in lumbar spine bone density, compared to 12% of those on teriparatide. At the total hip, 18% of the romosozumab group saw no increase, versus 60% on teriparatide.6SpringerLink (Journal of Bone and Mineral Metabolism). Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial Those numbers suggest that romosozumab builds bone more reliably than teriparatide in patients who have already been on bisphosphonates, particularly at the hip.
The early bone formation response was also more consistent with romosozumab. Within just one month, 95% of romosozumab-treated patients showed a meaningful rise in the bone formation marker P1NP, compared to 91% on teriparatide.6SpringerLink (Journal of Bone and Mineral Metabolism). Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial This rapid onset is part of what makes Evenity appealing for high-risk patients who need to build bone quickly.
The Cardiovascular Boxed Warning
Evenity carries a boxed warning about the risk of heart attack, stroke, and cardiovascular death. This is the most serious safety consideration and the reason the drug is reserved for patients at high fracture risk rather than being used broadly. The warning stems from findings in the ARCH trial, where romosozumab was compared to alendronate, and a higher rate of major adverse cardiovascular events was observed in the romosozumab group during the first year of treatment.
A pharmacovigilance analysis of the FDA’s adverse event reporting system found elevated reporting rates for the composite of major adverse cardiovascular events, with a reporting odds ratio of about 4.07 compared to other drugs in the database. When broken down by event type, the reporting odds ratios were roughly 3.10 for heart attack, 3.47 for stroke, and 4.90 for cardiovascular death.7Journal of Clinical Medicine. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) The elevated reporting was driven primarily by reports from Japan, where the drug was adopted early and widely. These are reporting ratios from a spontaneous adverse-event database, not incidence rates from a controlled trial, so they need careful interpretation. People are more likely to report events when they are already watching for them, and a boxed warning itself increases reporting. Still, the signal was strong enough to keep the warning in place.
In practical terms, this means your doctor should evaluate your cardiovascular history before prescribing Evenity. If you have had a heart attack or stroke within the past year, the drug is generally not recommended. For patients without recent cardiovascular events but with risk factors like high blood pressure or high cholesterol, the decision involves weighing fracture risk against heart risk on a case-by-case basis.
Calcium Levels During Treatment
When romosozumab stimulates bone formation, newly forming bone tissue pulls calcium out of the bloodstream to mineralize. This means your serum calcium can dip, especially early in treatment. A multicenter retrospective study found that serum calcium dropped by an average of 3.1% after the first month of treatment.8PubMed Central. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study None of the patients in that study reported symptoms of low calcium during the first month, suggesting that for most people the drop is modest and asymptomatic.
That said, the risk of a more meaningful calcium drop is higher in certain groups. Patients with vitamin D deficiency going into treatment, those with kidney problems, or those not taking adequate calcium and vitamin D supplements are more vulnerable. This is why prescribers typically check and correct vitamin D levels before starting Evenity, and why calcium and vitamin D supplementation throughout the 12-month course is considered standard practice rather than optional.
Using Evenity with Kidney Disease
Kidney disease is common in the older adults who need osteoporosis treatment, and many injectable drugs require dose adjustments when the kidneys are not working well. Evenity is an exception. Because romosozumab is a large monoclonal antibody, it is too big to be filtered by the kidneys. Instead, the body clears it through a completely different route involving the liver and the reticuloendothelial system. A phase 1 study in patients with advanced kidney disease, including those on hemodialysis, confirmed that kidney impairment does not meaningfully change how the drug behaves in the body.9PubMed Central. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease No dose adjustment is needed regardless of kidney function.
The efficacy picture is encouraging as well. Bone density improvements with romosozumab were similar across different levels of kidney function, meaning patients with mild-to-moderate chronic kidney disease gained just as much bone as those with healthy kidneys.9PubMed Central. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease However, patients with impaired kidneys are at higher risk for the calcium drop discussed earlier. For this group, more frequent calcium monitoring and diligent supplementation with calcium and vitamin D are recommended.10PubMed Central. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
Missing a Dose or Starting Late
Life happens, and monthly appointments are not always easy to keep. If you miss a scheduled Evenity injection, the general guidance is to reschedule as soon as possible and then continue with your regular monthly schedule from there. The drug does not need to be restarted from the beginning after a single missed dose. However, because the bone-building effect is front-loaded in the treatment course, missed doses in the early months are more costly in terms of cumulative bone gains than missed doses near the end. The early months are when bone formation markers are highest and when the drug delivers its most dramatic benefit.
There is no data supporting extending treatment beyond 12 monthly doses to “make up” for missed visits. The regulatory approval and the clinical trial evidence are based on 12 doses over roughly a year, and the body’s response to sclerostin inhibition wanes over that period regardless of whether you got every dose on time.
Injection-Site Reactions and Day-to-Day Tolerability
Beyond the cardiovascular warning, the most commonly reported side effects of Evenity are fairly mundane. Joint pain, headaches, and injection-site reactions top the list. The injection-site reactions, which can include redness, pain, or itching around the shot area, were tracked in a study that categorized 44 patients with reactions and 137 without over the first six months of treatment.2PubMed Central. Is Early Injection-Site Reaction Associated With the Efficacy of Romosozumab? That study was actually investigating whether having an injection-site reaction might be linked to how well the drug works, exploring whether local inflammation at the shot site signals a more vigorous biological response. The reactions themselves are the kind of thing most patients describe as a minor nuisance rather than a reason to stop treatment.
Compared to other injectable osteoporosis treatments, the monthly schedule is middle ground. Denosumab requires a shot only every six months but does not build new bone the way romosozumab does. Teriparatide requires daily self-injections for up to two years. Evenity’s 12 monthly visits represent a relatively finite commitment with a clear endpoint, which some patients find easier to stick with than an open-ended daily injection routine.
Cost and Insurance Realities
Evenity is expensive. The list price for a month’s supply of the two prefilled syringes runs into several thousand dollars in the United States, and a full 12-month course can approach or exceed $20,000 before insurance. Most commercial insurance plans and Medicare Part B do cover Evenity, but prior authorization is almost always required. Your prescriber typically needs to document that you have osteoporosis with high fracture risk, and many insurers require evidence that you have tried or cannot take a bisphosphonate first.
The manufacturer offers a patient assistance program for eligible individuals, and specialty pharmacies sometimes help navigate the insurance landscape. Even with coverage, copays can be substantial. If cost is a concern, it is worth asking your doctor’s office about support programs before the first injection rather than after you are midway through the course and facing unexpected bills.
Why Transition Therapy After Evenity Is Not Optional
One of the most under-appreciated aspects of Evenity treatment is that stopping after 12 months without starting another medication is essentially wasting the gains you just made. The bone that romosozumab builds is real, measurable, and protective against fractures, but it is not permanent without follow-up therapy. Bone is living tissue constantly being broken down and rebuilt, and once the sclerostin inhibitor is gone, the balance shifts back toward breakdown. Without an antiresorptive drug to slow that breakdown, bone density declines toward pre-treatment levels within a year or two.
In the FRAME trial, patients who received romosozumab for 12 months followed by denosumab continued to gain bone density and maintained fracture protection through 36 months.5PubMed. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial The sequence matters: romosozumab builds new bone rapidly, and denosumab or a bisphosphonate then locks those gains in place. Thinking of Evenity as a standalone treatment misunderstands how the drug fits into osteoporosis management. It is the first phase of a two-phase strategy, and the follow-up phase is what makes the initial investment in time, money, and cardiovascular risk worthwhile.